Country: Canada
Language: English
Source: Health Canada
ENOXAPARIN SODIUM
SHENZHEN TECHDOW PHARMACEUTICAL CO., LTD.
B01AB05
ENOXAPARIN
100MG
SOLUTION
ENOXAPARIN SODIUM 100MG
INTRAVENOUS
15G/50G
Prescription
HEPARINS
Active ingredient group (AIG) number: 0131860001; AHFS:
APPROVED
2020-12-07
Product Monograph REDESCA ® ( Enoxaparin sodium solution for injection) Page 1 of 78 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr REDESCA® Enoxaparin sodium solution for injection Solution for subcutaneous or intravenous injection, 100 mg/mL 30 mg/0.3 mL 40 mg/0.4 mL 60 mg/0.6 mL 80 mg/0.8 mL 100 mg/mL 300 mg/3 mL (manufacturer’s standard) Pr REDESCA HP® Enoxaparin sodium solution for injection Solution for subcutaneous or intravenous injection, 150 mg/mL (High Potency) 120 mg/0.8 mL 150 mg/mL (manufacturer’s standard) ATC Code: B01AB05 Anticoagulant/Antithrombotic Agent Shenzhen Techdow Pharmaceutical Co., Ltd. No. 1 Rongtian South, Kengzi Sub-district, Pingshan New District, Shenzhen City 518122 People’s Republic of China Date of Initial Authorization: December 7, 2020 Date of Revision: March 16, 2021 Submission Control Number: 231767 Product Monograph REDESCA ® (Enoxaparin sodium solution for injection) Page 2 of 78 RECENT MAJOR LABEL CHANGES Not Applicable TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed . RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .............................. Read the complete document